These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26861905)

  • 1. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
    Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
    Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of
    Mir O; Honoré C; Chamseddine AN; Dômont J; Dumont SN; Cavalcanti A; Faron M; Rimareix F; Haddag-Miliani L; Le Péchoux C; Levy A; Court C; Briand S; Fadel E; Mercier O; Bayle A; Brunet A; Ngo C; Rouleau E; Adam J; Le Cesne A
    Clin Cancer Res; 2020 Dec; 26(23):6277-6283. PubMed ID: 32873570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
    Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
    Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
    Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
    Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
    Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
    Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
    Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
    Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of
    Guo L; Wang X; Xu B; Lang R; Hu B
    Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
    Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
    Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological and molecular genetic features of neuromuscular choristoma-associated desmoid type fibromatosis].
    Dong RF; Guo W; Li N; Wang ZY; Sun XQ; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):685-690. PubMed ID: 38955699
    [No Abstract]   [Full Text] [Related]  

  • 19. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
    Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
    Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.